article thumbnail

Solving the $100,000 Cancer Drug Problem

Harvard Business Review

Last week over 100 leading cancer specialists signed their names to an op-ed in Blood , the journal of the American Society of Hematology, which lambasted the prices of cancer drugs that often exceed $100,000 annually. While pharma companies spend billions on research, the actual cost of manufacturing a treatment (such as a pill) is minimal.

article thumbnail

Why Tesco’s Strengths Are No Longer Good Enough

Harvard Business Review

There have always been convenience stores in the UK, but the shabby, independent corner shops are giving way to sparkling new outlets run by the supermarket chains full of fresh merchandise, albeit at premium prices. Aldi offers not just low prices, but convenience. You might wonder how anyone can make money with such low prices.

Retail 10